Astellas announced positive data from its study investigating the long-term safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Astellas Pharma announced positive results from its SKYLIGHT 4 clinical trial evaluating the long-term safety of fezolinetant, and oral, nonhormonal, selective neurokinin-3 (NK3) receptor antagonist, for the treatment moderate to severe vasomotor symptoms associated with menopause (VMS).1
“Vasomotor symptoms are often reported as the most bothersome symptoms of menopause, yet there has been very little innovation in this therapeutic area,” said Genevieve Neal-Perry, MD, PhD, chair of the Department of Obstetrics and Gynecology at the University of North Carolina School of Medicine. “I am excited by the potential of a new nonhormonal treatment option for women experiencing moderate to severe VMS associated with menopause.”
SKYLIGHT 4 (NCT04003389) is a phase 3, randomized, placebo-controlled, double-blind clinical trial evaluating the safety of fezolinetant in 1,800 women with VMS associated with menopause over 52 weeks.
The study’s goals were to evaluate the effect of fezolinetant on endometrial health, as well as the long-term safety and tolerability of fezolinetant. Also, the study achieved its primary endpoint of assessing endometrial health. Common treatment emergent adverse events (TEAE) included headache and COVID-19 and were consistent with placebo.
Astellas plans to present more details of the topline data at upcoming medical meetings and will use these data to support future regulatory submissions in the United States and Europe, according to a company press release.1
If approved, fezolinetant would be a first-in-class, nonhormonal treatment option to help reduce the severity and frequency of VMS associated with menopause.1
“Based on our initial assessment, we are pleased with the outcome of the SKYLIGHT 4 study, which further characterizes the long-term safety of fezolinetant,” said Nancy Martin, MD, PharmD, vice president and global medical head of medical specialties at Astellas. “With these fezolinetant data, we are hopeful that we will have the opportunity to deliver a first-in-class, nonhormonal treatment option for moderate to severe VMS associated with menopause.”
Reference
1. Astellas announces topline results from long-term phase 3 safety study of fezolinetant which inform future regulatory filings for the treatment of vasomotor symptoms associated with menopause. Astellas Pharma US, Inc. | News Room. Accessed March 11, 2022. https://newsroom.astellas.us/2022-03-07-Astellas-Announces-Topline-Results-from-Long-Term-Phase-3-Safety-Study-of-Fezolinetant-which-Inform-Future-Regulatory-Filings-for-the-Treatment-of-Vasomotor-Symptoms-Associated-with-Menopause
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Study links premature menopause to musculoskeletal pain and sarcopenia risks
May 1st 2024A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More